## Mehra Haghi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4005584/publications.pdf

Version: 2024-02-01

586496 563245 43 880 16 28 citations g-index h-index papers 43 43 43 1853 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate. Life Sciences, 2022, 300, 120574.	2.0	23
2	Advances and applications of dextran-based nanomaterials targeting inflammatory respiratory diseases. Journal of Drug Delivery Science and Technology, 2022, 74, 103598.	1.4	9
3	Manipulation of the Upper Respiratory Microbiota to Reduce Incidence and Severity of Upper Respiratory Viral Infections: A Literature Review. Frontiers in Microbiology, 2021, 12, 713703.	1.5	7
4	The Potential for Phospholipids in the Treatment of Airway Inflammation: An Unexplored Solution. Current Molecular Pharmacology, 2021, 14, 333-349.	0.7	1
5	Pharmacologic Inhibition of Vacuolar H <sup>+</sup> ATPase Attenuates Features of Severe Asthma in Mice. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 117-120.	1.4	6
6	Impact of A Cargo-Less Liposomal Formulation on Dietary Obesity-Related Metabolic Disorders in Mice. International Journal of Molecular Sciences, 2020, 21, 7640.	1.8	5
7	A phospholipid-based formulation for the treatment of airway inflammation in chronic respiratory diseases. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 157, 47-58.	2.0	15
8	Advancing of Cellular Signaling Pathways in Respiratory Diseases Using Nanocarrier Based Drug Delivery Systems. Current Pharmaceutical Design, 2020, 26, 5380-5392.	0.9	11
9	Role of Oxidative Stress in Complexity of Respiratory Diseases. , 2020, , 67-92.		O
10	Liposomes in the treatment of chronic respiratory conditions. , 2020, , 375-392.		3
11	A comparison of the cytotoxicity of different coals in lung epithelial cells. , 2020, , .		O
12	Human Stimulus Factor Is a Promising Peptide for Delivery of Therapeutics. Journal of Pharmaceutical Sciences, 2019, 108, 1401-1403.	1.6	2
13	High Fat Diet in Conjunction with Electronic Cigarette Vaping Worsens Lung Function and Inflammation. , 2019, , .		O
14	Autophagy Activation in Asthma Airways Remodeling. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 541-553.	1.4	108
15	Pro-inflammatory effects of exposure of the combination of silicon- and iron-containing particles upon human lung fibroblasts. , 2019, , .		O
16	A Simple and Rapid Method for Deposition and Measurement of Drug Transport Across Air Interface Respiratory Epithelia. AAPS PharmSciTech, 2018, 19, 3272-3276.	1.5	5
17	Profiling of healthy and asthmatic airway smooth muscle cells following interleukin- $1\hat{l}^2$ treatment: a novel role for CCL20 in chronic mucus hypersecretion. European Respiratory Journal, 2018, 52, 1800310.	3.1	38
18	Selective activation and targeting of autophagy in severe asthma. , 2018, , .		0

#	Article	IF	Citations
19	Autophagy and airway fibrosis: Is there a link?. F1000Research, 2017, 6, 409.	0.8	13
20	Autophagy and airway fibrosis: Is there a link?. F1000Research, 2017, 6, 409.	0.8	12
21	An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy. RSC Advances, 2016, 6, 25789-25798.	1.7	12
22	Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability. Expert Opinion on Drug Delivery, 2016, 13, 183-193.	2.4	27
23	Antibiotic transport across bronchial epithelial cells: Effects of molecular weight, LogP and apparent permeability. European Journal of Pharmaceutical Sciences, 2016, 83, 45-51.	1.9	14
24	The formulation of a pressurized metered dose inhaler containing theophylline for inhalation. European Journal of Pharmaceutical Sciences, 2015, 76, 68-72.	1.9	15
25	Inhalable tranexamic acid for haemoptysis treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 311-319.	2.0	16
26	A â€~soft spot' for drug transport: modulation of cell stiffness using fatty acids and its impact on drug transport in lung model. Journal of Materials Chemistry B, 2015, 3, 2583-2589.	2.9	13
27	Mono- and Cocultures of Bronchial and Alveolar Epithelial Cells Respond Differently to Proinflammatory Stimuli and Their Modulation by Salbutamol and Budesonide. Molecular Pharmaceutics, 2015, 12, 2625-2632.	2.3	16
28	In vitro biological activity of resveratrol using a novel inhalable resveratrol spray-dried formulation. International Journal of Pharmaceutics, 2015, 491, 190-197.	2.6	32
29	Development of an Inhaled Controlled Release Voriconazole Dry Powder Formulation for the Treatment of Respiratory Fungal Infection. Molecular Pharmaceutics, 2015, 12, 2001-2009.	2.3	35
30	Immunomodulatory Effects of a Low-Dose Clarithromycin-Based Macrolide Solution Pressurised Metered Dose Inhaler. Pharmaceutical Research, 2015, 32, 2144-2153.	1.7	13
31	Delivery of theophylline as dry powder for inhalation. Asian Journal of Pharmaceutical Sciences, 2015, 10, 520-527.	4.3	16
32	The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. Journal of Pharmacy and Pharmacology, 2014, 66, 639-645.	1.2	11
33	Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles in vitro. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 38-45.	2.0	19
34	Towards the bioequivalence of pressurised metered dose inhalers 1: Design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 31-37.	2.0	26
35	In Vitro Cell Integrated Impactor Deposition Methodology for the Study of Aerodynamically Relevant Size Fractions from Commercial Pressurised Metered Dose Inhalers. Pharmaceutical Research, 2014, 31, 1779-1787.	1.7	33
36	Across the pulmonary epithelial barrier: Integration of physicochemical properties and human cell models to study pulmonary drug formulations., 2014, 144, 235-252.		54

#	Article	IF	CITATION
37	Salbutamol Sulfate Absorption Across Calu-3 Bronchial Epithelia Cell Monolayer is Inhibited in the Presence of Common Anionic NSAIDs. Journal of Asthma, 2013, 50, 334-341.	0.9	18
38	Quercetin solid lipid microparticles: A flavonoid for inhalation lung delivery. European Journal of Pharmaceutical Sciences, 2013, 49, 278-285.	1.9	53
39	Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: Implications in the treatment of chronic obstructive airway pathologies. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 566-572.	2.0	23
40	Fluticasone uptake across Caluâ€3 cells is mediated by salmeterol when deposited as a combination powder inhaler. Respirology, 2013, 18, 1197-1201.	1.3	23
41	Modification of Disodium Cromoglycate Passage Across Lung Epithelium In Vitro Via Incorporation into Polymeric Microparticles. AAPS Journal, 2012, 14, 79-86.	2.2	4
42	Deposition, Diffusion and Transport Mechanism of Dry Powder Microparticulate Salbutamol, at the Respiratory Epithelia. Molecular Pharmaceutics, 2012, 9, 1717-1726.	2.3	51
43	Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Development and Industrial Pharmacy, 2010, 36, 1207-1214.	0.9	98